[O2-4] SARS2-5

[O2-4-16] Elucidation of molecular pathogenesis by which SARS-CoV2 gains cell entry: the study with human monoclonal antibodies

*Ryota Otsubo¹, Takeharu Minamitani², Kouji Kobiyama^3,7, Ken-Ichi Imadome⁴, Ken J. Ishii^3,7, Kouhei Tumoto^5,8,9, Wataru Kamitani⁶, Teruhito Yasui¹ (1. Laboratory of Infectious Diseases and Immunity, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, 2. Toyama Prefectural Institute for Pharmaceutical Research, 3. Division of Vaccine Science, Department of Microbiology and immunology, The institute of Medical Science, The University of Tokyo, 4. Department of Advanced Medicine for Infections, National Center for Child Health and Development, 5. Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, 6. Department of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, 7. Laboratory of Adjuvant Innovation, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, 8. Department of Bioengineering, School of Engineering, The University of Tokyo, 9. Institute of Medical Science, The University of Tokyo)